Randomized controlled trial shows silver nanoparticles enhance wound healing in urban TCFs, implying better patient outcomes.
Chronic wounds pose significant challenges in tertiary care facilities across South African cities, necessitating innovative solutions for effective management. A randomized controlled trial was conducted with participants from Tertiary Care Facilities (TCFs) across South African cities. Participants were randomly assigned to either a control group using conventional dressings or an experimental group receiving silver nanoparticle-based treatments. Wound healing outcomes and safety profiles were evaluated at baseline, three months, and six months post-treatment. A total of 150 participants completed the study. The silver nanoparticle group showed significantly faster wound closure rates compared to controls (p < 0.001), with an average improvement in healing time by 32% over six months, indicating a substantial therapeutic effect. Silver nanoparticles demonstrated efficacy and safety for chronic wound healing in urban TCF settings. These findings support the clinical adoption of silver nanoparticle-based therapies to enhance wound management outcomes. Further research is recommended to explore long-term effects and potential synergies with other treatments, while ensuring regulatory compliance for widespread use. Treatment effect was estimated with logit(pᵢ)=β₀+β^ Xᵢ, and uncertainty reported using confidence-interval based inference.
No takes yet. Share an insight, caveat, or question.
Siyavhuwa Mkhize (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: